β-elemene suppresses the malignant behavior of esophageal cancer cells by regulating the phosphorylation of AKT

Liang, Yufei; Li, Shengmian; Guo, Zheng; Zhang, Lan

doi:10.1016/j.acthis.2020.151538

Cited by 16 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liang et al found that β-elemene suppressed PD-L1 expression and cancer cell proliferation in esophageal cancer cells. In both in vitro and in vivo experiments, β-elemene consistently inhibited Akt activation as well as expression of its downstream molecule, PD-L1 [199]. Although the general mechanism by which β-elemene suppresses tumors remains unclear, several studies have drawn attention to Akt as a target [222][223][224][225].…”

Section: β-Elemenementioning

confidence: 99%

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

et al. 2021

View full text Add to dashboard Cite

The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulating the immune system with ICIs still faces obstacles with severe immunogenic side effects and a lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have been applied for the treatment of multiple diseases, including cancer. Accumulated evidence provides the possibility of efficacy of phytochemicals in combinational with other therapeutic agents of ICIs, effectively modulating immune checkpoint-related signaling molecules. Recently, several phytochemicals have been reported to show the modulatory effects of immune checkpoints in various cancers in in vivo or in vitro models. This review summarizes druggable immune checkpoints and their regulatory factors. In addition, phytochemicals that are capable of suppressing PD-1/PD-L1 binding, the best-studied target of ICI therapy, were comprehensively summarized and classified according to chemical structure subgroups. It may help extend further research on phytochemicals as candidates of combinational adjuvants. Future clinical trials may validate the synergetic effects of preclinically investigated phytochemicals with ICI therapy.

show abstract

Section: β-Elemenementioning

confidence: 99%

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…β-Elemene (1-methyl-1-vinyl-2,4-diisopropenyl-cyclohexane), extracted from the root of Curcuma wenyujin , presents a broad-spectrum, moderate, antitumor effect and is widely used as an adjunctive drug to enhance the efficacy, reduce the toxicity of chemoradiotherapy, and reverse drug resistance in cancer treatment. 43 Previous studies have indicated that β‐elemene could inhibit cell proliferation and induce apoptosis in various types of cancers, including melanoma, 44 hepatocellular, 23 lymphoma, 26 glioma, 29 esophageal, 31 gastric, 45 glioblastoma multiforme, 32 nonsmall-cell lung, 33 pancreatic, 39 and nasopharyngeal. 34 Recent studies have reported that β‐elemene significantly inhibited the migration and invasive capacity of BGC823, SGC7901 and multidrug resistant (MDR) SGC7901/ADR gastric cancer cells, TE-1 and KYSE-150 esophageal cancer cells in vitro and inhibited the capacity of BGC823 cells to diffuse peritoneally and metastasize in vivo.…”

Section: Pharmacologymentioning

confidence: 99%

“…34 Recent studies have reported that β‐elemene significantly inhibited the migration and invasive capacity of BGC823, SGC7901 and multidrug resistant (MDR) SGC7901/ADR gastric cancer cells, TE-1 and KYSE-150 esophageal cancer cells in vitro and inhibited the capacity of BGC823 cells to diffuse peritoneally and metastasize in vivo. 24,25,31 Moreover, the radio sensitivity of cancers, such as glioblastoma multiforme U87-MG, T98G, and U251 cells, 32 melanoma A375 cells, 44 and A549 lung adenocarcinoma xenograft 27,28 were also reported to be significantly enhanced by β-elemene.…”

Section: Pharmacologymentioning

confidence: 99%

“…It modulated Ki67, PCNA, mitogen-activated protein kinase kinase-3 (MKK3), MKK-6, and cyclin proteins to arrest the cell cycle 31,35,38 and regulated the expression of relative proteins such as the long non-coding RNA (lncRNA) highly up-regulated in liver cancer (HULC), survivin, caspase-3,‐8 and −9, PERK, IRE1α, ATF6, Hsp90/Raf-1, Fas/FasL, and Bcl-2/BAX proteins to induce cell apoptotic death of cancer cells. 26,27,29,33,35,37 In addition, β-elemene performed synergistic or directly suppressive effects through targeting histone H1, 23 copper transporter 1 (CTR1), 30 E3 ubiquitin ligase Cbl, 36 signal transducer, and activator of transcription 3 (Stat3), DNA methyltransferase 1 (DNMT1), enhancer of zeste homolog 2 (EZH2), 34 hypoxia inducible factor 1 subunit α (HIF1α), vascular endothelial growth factor A (VEGFA), 39 PTEN, 31 and ataxia telangiectasia mutated (ATM) signaling pathways. 32 Furthermore, β-elemene inhibited tumor angiogenesis and metastasis through regulation of crucial molecules, such as Claudin-1 by downregulating FAK phosphorylation, 24 MMP-2/9 via modulating Cbl-b/EGFR/ERK/AKT signaling 25 and programmed cell death 1-ligand 1 (PD-L1) by regulating p-AKT.…”

Section: Pharmacologymentioning

confidence: 99%

“…32 Furthermore, β-elemene inhibited tumor angiogenesis and metastasis through regulation of crucial molecules, such as Claudin-1 by downregulating FAK phosphorylation, 24 MMP-2/9 via modulating Cbl-b/EGFR/ERK/AKT signaling 25 and programmed cell death 1-ligand 1 (PD-L1) by regulating p-AKT. 31 β-Elemene was also found to reverse epithelial-mesenchymal transition (EMT) in MDR gastric cancer cells by inhibiting the transcription factors ZEB1 and ZEB2 that contribute to antitumor metastatic activities. 25 Moreover, the radiation-induced HIF1α and peroxiredoxin-1 (Prx-1) expression were significantly suppressed by β-elemene, which reversed the radio-resistance of the human lung cancer.…”

Section: Pharmacologymentioning

confidence: 99%

See 2 more Smart Citations

A Comprehensive Mini-Review of Curcumae Radix: Ethnopharmacology, Phytochemistry, and Pharmacology

Gao

Yang

et al. 2021

Natural Product Communications

View full text Add to dashboard Cite

Curcumae Radix is an efficacious ingredient with various medicinal properties empirically used in traditional Chinese medicine (TCM) formula for the treatment of cancer, depression, chest pain, dysmenorrhea, epilepsy, and jaundice. However, either phytochemical or pharmacological information of Curcumae Radix underlying its traditionally medicinal uses is rarely summarized and systematically analyzed. To provide evidence for clinical trials, a comprehensive literature review has been prepared of the phytochemicals, and ethnopharmacological and pharmacological mechanisms of this herb. The review approach consisted of searching several web-based scientific databases, including PubMed, Web of Science, and Elsevier. The keywords included “Curcumae Radix,” “ Curcuma wenyujin,” “ Curcuma longa,” “ Curcuma kwangsiensis,” and “ Curcuma phaeocaulis.” Based on the proposed criteria, 57 articles were evaluated in detail. The accumulated data indicate that Curcumae Radix contains a number of bioactive phytochemicals, mainly sesquiterpenes, diarylheptanoids, and diarylpentanoids, which account for a variety of medicinal values, such as anticancer, anti-inflammation, anti-hepatic fibrosis, and antioxidant. A wide range of apoptotic proteins, cell adhesion molecules, inflammatory cytokines, and enzymic and nonenzymic antioxidants could be modulated by either Curcumae Radix or its bioactive compounds, thus underpinning a fundamental understanding for the pharmacological effects of this herb. This review highlights the therapeutic potential of Curcumae Radix to progress the development of versatile adjuvants or therapeutic agents in the future.

show abstract

Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets

Zhong

Vong

Chen

et al. 2022

Medicinal Research Reviews

View full text Add to dashboard Cite

Immunotherapy sheds new light to cancer treatment and is satisfied by cancer patients. However, immunotoxicity, single-source antibodies, and single-targeting stratege are potential challenges to the success of cancer immunotherapy. A huge number of promising lead compounds for cancer treatment are of natural origin from herbal medicines. The application of natural products from herbal medicines that have immunomodulatory properties could alter the landscape of immunotherapy drastically. The present study summarizes current medication for cancer immunotherapy and discusses the potential chemicals from herbal medicines as immune checkpoint inhibitors that have a broad range of

show abstract

β-elemene suppresses the malignant behavior of esophageal cancer cells by regulating the phosphorylation of AKT

Cited by 16 publications

References 38 publications

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

A Comprehensive Mini-Review of Curcumae Radix: Ethnopharmacology, Phytochemistry, and Pharmacology

Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets

Contact Info

Product

Resources

About